Clinical trials: Acute Coronary Syndromes
Coronary Stenosis, Acute Coronary Syndrome
Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
The aim of Multiplaque clinical study is to assess the vulnerability degree of the atheromatous plaques, before and after a myocardial infarction (MI), based on multiomics analysis, associated with invasive and non-invasive data.
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- MultiPlaque (NCT03391908)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Myocardial Infarction, Acute Coronary Syndromes
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is…
- Conditions
- Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
- Trial name
- SAVI-PCI (NCT01522417)
- Testing
- Short Tirofiban, Eptifibatide, Long Tirofiban
- Where
- 13 sites in United States
- Volunteers
- 535 people
- Sponsor
- Medicure
Acute Coronary Syndromes
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
To investigate how platelets recover to normal function in subjects who have symptoms of a heart attack or unstable angina and who get a loading dose of prasugrel or clopidogrel for planned coronary angiography.
- Trial name
- NCT01107899
- Testing
- clopidogrel, prasugrel
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Myocardial Ischemia
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately…
- Trial name
- NCT00099788
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 6,560 people
- Sponsor
- Gilead Sciences
Severe Sepsis, Acute Heart Failure
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
The purpose of this study is to evaluate the impact that the Venus 1000 non-invasive CVP system has on the management of emergency department (ED) patients with fluid sensitive conditions.
- Trial name
- NCT02258984
- Testing
- Mespere Venus 1000 Non-Invasive CVP System
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mespere Lifesciences Inc.
Severe Sepsis, Cardiac Arrest
Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes
A hospitals manual method of patient monitoring will be implemented in an automated system and supported by an early patient deterioration detection for timely escalation.
- Conditions
- Severe Sepsis, Cardiac Arrest, Respiratory Failure
- Trial name
- NCT01692847
- Where
- United Kingdom
- Volunteers
- 678 people
- Sponsor
- Philips Healthcare
Acute Coronary Syndrome
Clinical Study to Validate the Use of a New Point of Care Troponin I Test
This trial is designed as a prospective, multi-center, observational study of "all-comers" eligible adult subjects presenting to participating emergency departments with symptoms suggestive of acute coronary syndrome (ACS)
- Trial name
- NCT02620397
- Where
- 14 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Trinity Biotech
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Myocardial Ischemia, Acute Coronary Syndrome
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention…
- Trial name
- NCT00089895
- Testing
- Eptifibatide (Integrilin)
- Volunteers
- 9,406 people
- Sponsor
- Organon and Co
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Acute Coronary Syndrome
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12…
- Trial name
- GEMINI ACS 1 (NCT02293395)
- Testing
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel
- Where
- 259 sites in United States, Argentina and 18 more
- Volunteers
- 3,037 people
- Sponsor
- Janssen Research & Development, LLC
Acute Coronary Syndrome
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective, observational longitudinal study to evaluate the real…
- Trial name
- TRANSLATE-ACS (NCT01088503)
- Testing
- ADP receptor inhibitors
- Where
- 186 sites in United States, Puerto Rico
- Volunteers
- 12,227 people
- Sponsor
- Eli Lilly and Company
Peripheral Vascular Diseases
Screening DIVA - Diffuse Vascular Disease
Primary Objective: To investigate the value of the Edinburgh Claudication Questionnaire (ECQ) against the ankle-brachial index (ABI) in Canadian patients mainly followed in general practice, with documented acute coronary…
- Trial name
- NCT01076738
- Where
- Canada
- Volunteers
- 2,233 people
- Sponsor
- Sanofi
Heart Failure, Acute Coronary Syndromes
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method）
The aim of the study is to evaluate diagnostic performance of N-terminal Brain natriuretic Peptide (NT-proBNP) in acute heart failure among Chinese population.
- Trial name
- NT-proBNP，HF (NCT06691477)
- Testing
- No Interventions
- Where
- 4 sites in China
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- Beckman Coulter, Inc.
Acute Coronary Syndrome
OPTIMIZE IDE for the Treatment of ACS
Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery…
- Trial name
- OPTIMIZE (NCT03190473)
- Testing
- DES
- Where
- 72 sites in United States, Japan and 1 more
- Volunteers
- 1,630 people
- Sponsor
- Svelte Medical Systems, Inc.
Acute Coronary Syndromes
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
The primary objective of the UPSTREAM Registry is to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by…
- Trial name
- NCT02271022
- Testing
- Non-Interventional Study
- Where
- 55 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (eg, aspirin, clopidogrel) for preventing heart attack and stroke in patients with acute coronary syndrome, will yield additional…
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00527943
- Testing
- Vorapaxar
- Volunteers
- 12,944 people
- Sponsor
- Merck Sharp & Dohme LLC
Atherosclerotic Cardiovascular Disease, Acute Coronary Syndromes
Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort
The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)/pharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its…
- Trial name
- CTx-001 (NCT06813339)
- Testing
- UDP-003
- Where
- 3 sites in Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Cyclarity Therapeutics, Inc.
Coronary Arteriosclerosis, Acute Coronary Syndromes
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a…
- Trial name
- NCT00097591
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 13,619 people
- Sponsor
- Eli Lilly and Company